An open study of interferon in HIV-antibody-positive men.
Alpha-2a-recombinant interferon (Roferon A) was given subcutaneously in a dose of 3 mega units twice weekly for 15-18 months to 14 HIV-antibody-positive, p24-antigen-negative men with minimal HIV-related disease. Interferon was well-tolerated and safe. Although there was either improvement or lack of deterioration initially in 22 out of 26 HIV disease markers, including lymphadenopathy, thrombocytopenic purpura and nail fungal infection, there were 11 instances of HIV disease indicators appearing during the study. At 15 months, six patients were withdrawn from the study because of clinical and immunological deterioration.
Ellis
M E
ME
Regional Department of Infectious Diseases, Monsall Hospital, Salford, UK.
Haeney
M R
MR
Craske
J
J
Potter
M R
MR
Turner
A J
AJ
Shipman
J
J
Blackburn
N
N
D000328:Adult; D015496:CD4-Positive T-Lymphocytes; D015683:Gene Products, gag / Q000032:analysis; D015488:HIV Antigens / Q000032:analysis; D016655:HIV Core Protein p24; D015658:HIV Infections / Q000628:therapy*; D006679:HIV Seropositivity; D006801:Humans; D007279:Injections, Subcutaneous; D007370:Interferon Type I / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D007958:Leukocyte Count; D008214:Lymphocytes; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D012646:Self Administration; D050378:T-Lymphocytes, Regulatory; D014758:Viral Core Proteins / Q000032:analysis
D015683:Gene Products, gag; D015488:HIV Antigens; D016655:HIV Core Protein p24; D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D014758:Viral Core Proteins